Wealth of positive data for Roche in ophthalmology

12 February 2021
2020_roche_big

Swiss pharma major Roche (ROG: SIX) has revealed detailed results from four Phase III studies of its investigational ophthalmic therapy, faricimab, a bispecific antibody.

Roche is testing the candidate, which has a favorable dosing regimen compared with alternatives, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD).

The firm said its data showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to Eylea (aflibercept), which must be given every two months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology